You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylphenobarbital
Accession NumberDB00849  (APRD00047)
TypeSmall Molecule
GroupsApproved
DescriptionA barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital. [PubChem]
Structure
Thumb
Synonyms
1-Methylphenobarbital
5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-1-methyl-5-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-1-methyl-5-phenylbarbituric acid
Enphenemal
Mebaral
Mephobarbital
Mephobarbitone
Méthylphénobarbital
Methylphenobarbital
Methylphenobarbitalum
Methylphenobarbitone
Metilfenobarbital
Metilfenobarbitale
N-Methylphenobarbital
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MebaralLundbeck A/S
MephyltalettenNot Available
PhemitonNot Available
PhemitoneNot Available
PhenmitonNot Available
ProminalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5NC67NU76B
CAS number115-38-8
WeightAverage: 246.2619
Monoisotopic: 246.100442324
Chemical FormulaC13H14N2O3
InChI KeyALARQZQTBTVLJV-UHFFFAOYSA-N
InChI
InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
IUPAC Name
5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1
Pharmacology
IndicationFor the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.
Structured Indications Not Available
PharmacodynamicsMethylphenobarbital, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Mechanism of actionMethylphenobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
potentiator
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
potentiator
HumanQ16445 details
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
antagonist
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
antagonist
HumanP36544 details
Glutamate receptor 2Proteinunknown
antagonist
HumanP42262 details
Glutamate receptor ionotropic, kainate 2Proteinunknown
antagonist
HumanQ13002 details
Related Articles
AbsorptionApproximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding70-76%
Metabolism

Hepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours.

SubstrateEnzymesProduct
Methylphenobarbital
Not Available
PhenobarbitalDetails
Route of eliminationNot Available
Half life34 (range 11-67) hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Methylphenobarbital can be decreased when combined with Abiraterone.Approved
AcebutololMethylphenobarbital may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Methylphenobarbital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Methylphenobarbital.Approved
AcetazolamideMethylphenobarbital may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Agomelatine.Approved, Investigational
AldesleukinMethylphenobarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methylphenobarbital.Approved, Illicit
AliskirenMethylphenobarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methylphenobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Methylphenobarbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Methylphenobarbital.Experimental
AmifostineMethylphenobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideMethylphenobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Methylphenobarbital.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Methylphenobarbital.Approved
AmiodaroneMethylphenobarbital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Methylphenobarbital.Approved
AmlodipineMethylphenobarbital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amperozide.Experimental
Amphotericin BMethylphenobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Methylphenobarbital.Approved
Amyl NitriteMethylphenobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Methylphenobarbital.Investigational
ApomorphineMethylphenobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineMethylphenobarbital may increase the hypotensive activities of Apraclonidine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Methylphenobarbital can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Methylphenobarbital.Approved
Arsenic trioxideMethylphenobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Asenapine.Approved
AtenololMethylphenobarbital may increase the hypotensive activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Azaperone.Vet Approved
AzelastineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Methylphenobarbital.Approved
Azilsartan medoxomilMethylphenobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Methylphenobarbital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Methylphenobarbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Methylphenobarbital.Experimental
BenazeprilMethylphenobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Methylphenobarbital.Approved
BenperidolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Methylphenobarbital.Approved, Withdrawn
BetaxololMethylphenobarbital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital.Approved
BisoprololMethylphenobarbital may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Methylphenobarbital.Approved
BortezomibThe metabolism of Methylphenobarbital can be decreased when combined with Bortezomib.Approved, Investigational
BretyliumMethylphenobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Bromazepam.Approved, Illicit
BromocriptineMethylphenobarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Methylphenobarbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Methylphenobarbital.Experimental, Investigational
BumetanideMethylphenobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methylphenobarbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Methylphenobarbital.Approved
BuprenorphineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylphenobarbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methylphenobarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylphenobarbital.Approved, Illicit, Vet Approved
CaiThe metabolism of Cai can be increased when combined with Methylphenobarbital.Investigational
CanagliflozinMethylphenobarbital may increase the hypotensive activities of Canagliflozin.Approved
CandesartanMethylphenobarbital may increase the hypotensive activities of Candesartan.Approved
CaptoprilMethylphenobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Methylphenobarbital can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinMethylphenobarbital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carisoprodol.Approved
CarteololMethylphenobarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolMethylphenobarbital may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Methylphenobarbital.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Methylphenobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methylphenobarbital.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloroprocaine.Approved
ChlorothiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Methylphenobarbital.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenobarbital.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Methylphenobarbital can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilMethylphenobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Methylphenobarbital.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Methylphenobarbital.Approved
CimetidineThe metabolism of Methylphenobarbital can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methylphenobarbital.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Methylphenobarbital.Approved
CitalopramThe metabolism of Methylphenobarbital can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clemastine.Approved
ClevidipineMethylphenobarbital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clobazam.Approved, Illicit
ClofarabineMethylphenobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Methylphenobarbital.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clonidine.Approved
ClopidogrelThe metabolism of Methylphenobarbital can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylphenobarbital.Approved, Illicit
ClotrimazoleThe metabolism of Methylphenobarbital can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenobarbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methylphenobarbital.Approved, Illicit
ConivaptanMethylphenobarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Methylphenobarbital.Approved
CrizotinibThe metabolism of Methylphenobarbital can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Methylphenobarbital.Approved
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dantrolene.Approved
DapagliflozinMethylphenobarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenobarbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Methylphenobarbital.Experimental
DelavirdineThe metabolism of Methylphenobarbital can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Methylphenobarbital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Methylphenobarbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methylphenobarbital.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methylphenobarbital.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methylphenobarbital.Approved, Illicit, Vet Approved
DiclofenamideMethylphenobarbital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Methylphenobarbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Methylphenobarbital.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Methylphenobarbital.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Methylphenobarbital.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemMethylphenobarbital may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dimenhydrinate.Approved
DinutuximabMethylphenobarbital may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Diphenoxylate.Approved, Illicit
DipyridamoleMethylphenobarbital may increase the hypotensive activities of Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Methylphenobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Methylphenobarbital.Investigational
DoxazosinMethylphenobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Methylphenobarbital.Approved
DoxorubicinThe metabolism of Methylphenobarbital can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Methylphenobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Methylphenobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Methylphenobarbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Methylphenobarbital.Approved
EmpagliflozinMethylphenobarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilMethylphenobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMethylphenobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methylphenobarbital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Entacapone.Approved, Investigational
EperisoneThe metabolism of Eperisone can be increased when combined with Methylphenobarbital.Approved, Investigational
EplerenoneMethylphenobarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolMethylphenobarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanMethylphenobarbital may increase the hypotensive activities of Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Methylphenobarbital can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Methylphenobarbital.Investigational
EsmololMethylphenobarbital may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Methylphenobarbital can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Estazolam.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Methylphenobarbital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Methylphenobarbital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Methylphenobarbital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Methylphenobarbital.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methylphenobarbital.Approved
Etacrynic acidMethylphenobarbital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methylphenobarbital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Methylphenobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Methylphenobarbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Methylphenobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Methylphenobarbital can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ezogabine.Approved
FelbamateThe serum concentration of Methylphenobarbital can be increased when it is combined with Felbamate.Approved
FelodipineMethylphenobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Methylphenobarbital.Withdrawn
FenoldopamMethylphenobarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylphenobarbital.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fexofenadine.Approved
FimasartanMethylphenobarbital may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flibanserin.Approved
FluconazoleThe metabolism of Methylphenobarbital can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Methylphenobarbital.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Methylphenobarbital can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenobarbital.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methylphenobarbital.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Methylphenobarbital can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilMethylphenobarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Methylphenobarbital can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fospropofol.Approved, Illicit
FurosemideMethylphenobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with gabapentin enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Methylphenobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Methylphenobarbital can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Methylphenobarbital.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Methylphenobarbital.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methylphenobarbital.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenobarbital.Approved
HalothaneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Methylphenobarbital.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hexobarbital.Approved
HydralazineMethylphenobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylphenobarbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Iloperidone.Approved
IloprostMethylphenobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilMethylphenobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Methylphenobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideMethylphenobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Methylphenobarbital.Withdrawn
IndinavirThe metabolism of Methylphenobarbital can be decreased when combined with Indinavir.Approved
IndoraminMethylphenobarbital may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanMethylphenobarbital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidMethylphenobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methylphenobarbital.Approved, Vet Approved
IsoniazidThe metabolism of Methylphenobarbital can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateMethylphenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateMethylphenobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineMethylphenobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineMethylphenobarbital may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Methylphenobarbital can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolMethylphenobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Methylphenobarbital.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Methylphenobarbital.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Methylphenobarbital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levetiracetam.Approved, Investigational
LevobunololMethylphenobarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Methylphenobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levorphanol.Approved
LevosimendanMethylphenobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methylphenobarbital.Approved, Vet Approved
LisinoprilMethylphenobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lofentanil.Illicit
LofexidineMethylphenobarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Methylphenobarbital can be increased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methylphenobarbital.Approved
LosartanMethylphenobarbital may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenobarbital.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Methylphenobarbital can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methylphenobarbital can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Methylphenobarbital.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Methylphenobarbital.Approved
MannitolMethylphenobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Maprotiline.Approved
MecamylamineMethylphenobarbital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Methylphenobarbital.Approved, Investigational
MefloquineThe therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mesoridazine.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Methylphenobarbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methylphenobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Methylphenobarbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideMethylphenobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methylphenobarbital.Approved
MethotrimeprazineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methsuximide.Approved
MethyclothiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaMethylphenobarbital may increase the hypotensive activities of Methyldopa.Approved
MetipranololMethylphenobarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMethylphenobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololMethylphenobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineMethylphenobarbital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Methylphenobarbital.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved, Investigational
MinoxidilMethylphenobarbital may increase the hypotensive activities of Minoxidil.Approved
MirtazapineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Methylphenobarbital can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Methylphenobarbital can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMethylphenobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methylphenobarbital.Approved, Investigational
MoxonidineMethylphenobarbital may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved, Investigational
NadololMethylphenobarbital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Methylphenobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylphenobarbital.Approved
NebivololMethylphenobarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Methylphenobarbital can be decreased when combined with Nelfinavir.Approved
NesiritideMethylphenobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NevirapineThe metabolism of Methylphenobarbital can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Methylphenobarbital can be decreased when combined with Nicardipine.Approved
NifedipineMethylphenobarbital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Methylphenobarbital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Methylphenobarbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Methylphenobarbital.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Methylphenobarbital.Approved, Withdrawn
NimodipineMethylphenobarbital may increase the hypotensive activities of Nimodipine.Approved
NisoldipineMethylphenobarbital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nitrazepam.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Methylphenobarbital.Approved
Nitric OxideMethylphenobarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinMethylphenobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideMethylphenobarbital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Methylphenobarbital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Methylphenobarbital.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Methylphenobarbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Methylphenobarbital.Approved
ObinutuzumabMethylphenobarbital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital.Approved, Investigational
OlmesartanMethylphenobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Methylphenobarbital can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ondansetron.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Methylphenobarbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Methylphenobarbital can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methylphenobarbital.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenobarbital.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelMethylphenobarbital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paliperidone.Approved
PantoprazoleThe metabolism of Methylphenobarbital can be decreased when combined with Pantoprazole.Approved
PapaverineMethylphenobarbital may increase the hypotensive activities of Papaverine.Approved
ParaldehydeMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Methylphenobarbital can be decreased when combined with Paroxetine.Approved, Investigational
PenbutololMethylphenobarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methylphenobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Methylphenobarbital.Approved
PerindoprilMethylphenobarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perphenazine.Approved
PethidineMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineMethylphenobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Methylphenobarbital.Approved
PhenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineMethylphenobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Methylphenobarbital.Approved
PhentolamineMethylphenobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Methylphenobarbital can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pimozide.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Methylphenobarbital.Approved
PindololMethylphenobarbital may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pizotifen.Approved
PolythiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pomalidomide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Methylphenobarbital.Approved
PramipexoleMethylphenobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Prazepam.Approved, Illicit
PrazosinMethylphenobarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methylphenobarbital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pregnanolone.Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Methylphenobarbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methylphenobarbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methylphenobarbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methylphenobarbital.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenobarbital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenobarbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Methylphenobarbital.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methylphenobarbital.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methylphenobarbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Propoxycaine.Approved
PropranololMethylphenobarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Methylphenobarbital.Approved
PSD502The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with PSD502.Investigational
PyridoxineThe metabolism of Methylphenobarbital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe serum concentration of Methylphenobarbital can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Quetiapine.Approved
QuinaprilMethylphenobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneMethylphenobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ramelteon.Approved, Investigational
RamiprilMethylphenobarbital may increase the hypotensive activities of Ramipril.Approved
RasagilineMethylphenobarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenobarbital.Approved
RifabutinThe metabolism of Methylphenobarbital can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Methylphenobarbital can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Methylphenobarbital can be increased when combined with Rifapentine.Approved
RiociguatMethylphenobarbital may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Methylphenobarbital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenobarbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Romifidine.Vet Approved
RopiniroleMethylphenobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylphenobarbital.Approved
RotigotineMethylphenobarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methylphenobarbital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with S-Ethylisothiourea.Experimental
SacubitrilMethylphenobarbital may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylphenobarbital.Approved, Vet Approved
SelegilineMethylphenobarbital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Methylphenobarbital can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteMethylphenobarbital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Methylphenobarbital.Approved
SorafenibThe metabolism of Methylphenobarbital can be decreased when combined with Sorafenib.Approved, Investigational
SotalolMethylphenobarbital may increase the hypotensive activities of Sotalol.Approved
SpironolactoneMethylphenobarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe metabolism of Methylphenobarbital can be decreased when combined with Stiripentol.Approved
StreptokinaseMethylphenobarbital may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital.Approved
SuvorexantMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Methylphenobarbital.Approved
TamsulosinMethylphenobarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tasimelteon.Approved
TelmisartanMethylphenobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methylphenobarbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Methylphenobarbital.Approved
TerazosinMethylphenobarbital may increase the hypotensive activities of Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrodotoxin.Investigational
ThalidomideMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Methylphenobarbital.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methylphenobarbital.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenobarbital.Approved
ThiotepaThe metabolism of Methylphenobarbital can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Methylphenobarbital.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiapride.Investigational
TiclopidineThe metabolism of Methylphenobarbital can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiletamine.Vet Approved
TimololMethylphenobarbital may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tizanidine.Approved
TolazolineMethylphenobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Methylphenobarbital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Topiramate.Approved
TorasemideMethylphenobarbital may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methylphenobarbital.Approved, Investigational
TrandolaprilMethylphenobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Methylphenobarbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylphenobarbital.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methylphenobarbital.Approved, Investigational
TretinoinMethylphenobarbital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneMethylphenobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triazolam.Approved
TrichlormethiazideMethylphenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenobarbital.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenobarbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Methylphenobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Methylphenobarbital.Approved
Valproic AcidThe serum concentration of Methylphenobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanMethylphenobarbital may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Methylphenobarbital can be decreased when combined with Venlafaxine.Approved
VerapamilMethylphenobarbital may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Methylphenobarbital.Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Methylphenobarbital.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Methylphenobarbital.Approved
XylazineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Methylphenobarbital.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenobarbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zolazepam.Vet Approved
ZolpidemMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN03AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.9859
Caco-2 permeable+0.5674
P-glycoprotein substrateNon-substrate0.6107
P-glycoprotein inhibitor INon-inhibitor0.5213
P-glycoprotein inhibitor IINon-inhibitor0.8987
Renal organic cation transporterNon-inhibitor0.8913
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateNon-substrate0.6613
CYP450 1A2 substrateNon-inhibitor0.857
CYP450 2C9 inhibitorNon-inhibitor0.6815
CYP450 2D6 inhibitorNon-inhibitor0.9404
CYP450 2C19 inhibitorNon-inhibitor0.7403
CYP450 3A4 inhibitorNon-inhibitor0.935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9254
Ames testNon AMES toxic0.727
CarcinogenicityNon-carcinogens0.754
BiodegradationNot ready biodegradable0.9668
Rat acute toxicity2.6756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Mentax 1% cream4.0USD g
Mebaral 100 mg tablet1.73USD tablet
Mebaral 50 mg tablet1.28USD tablet
Mebaral 32 mg tablet0.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point176 °CPhysProp
water solubilitySlightly solubleNot Available
logP1.84HANSCH,C ET AL. (1995)
pKa7.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.71 mg/mLALOGPS
logP1.95ALOGPS
logP1.63ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)8.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.64 m3·mol-1ChemAxon
Polarizability24.62 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.57 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • Benzenoid
  • 1,3-diazinane
  • Monocyclic benzene moiety
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  7. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  8. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
  9. Roden WH, Peugh LD, Jansen LA: Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex. Neurosci Lett. 2010 Oct 15;483(3):167-72. doi: 10.1016/j.neulet.2010.08.001. Epub 2010 Aug 6. [PubMed:20692323 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  3. Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. doi: 10.1007/s12630-010-9429-7. Epub 2010 Dec 31. [PubMed:21194017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23